CRESCENT BIOPHARMA, INC. (CBIO)
Data as of , from SEC Form 4 filings.
Net insider buying (90d)Watch CBIO
See up to 3 months of CBIO. The 7-day demo opens the 1M and 3M ranges and puts CBIO on your watchlist.
Start 7-day demoLatest CBIO insider trades
Ryan Lynch - OfficerOpen-market sale$4K
Jan Pinkas - OfficerOpen-market sale
About CRESCENT BIOPHARMA, INC. (CBIO)
CRESCENT BIOPHARMA, INC. is an SEC registrant, filing under CIK 0001253689, classified as pharmaceutical preparations. We track it alongside the rest of the Health Care sector. It filed a registration statement with the SEC on 7 January 2026 and has not yet priced an offering.
CBIO Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 2 | 1,379,347 | $20.00M |
| Open-market sale | 9 | 16,726 | $286K |
CBIO insider transactions (Form 4)
3527 Form 4 filings on record, the earliest from Jun 13, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Ryan Lynch - Officer | Open-market sale | Ordinary Shares | 240 footnote F1 | $17.90 footnote F2 | $4K | |
| ||||||
| Jan Pinkas - Officer | Open-market sale | Ordinary Shares | 658 footnote F1 | $17.90 footnote F2 | $12K | |
| ||||||
| Ellie Eunkyung Im - Officer | Open-market sale | Ordinary Shares | 623 footnote F1 | $17.90 footnote F2 | $11K | |
| ||||||
| Richard William Scalzo - Officer | Open-market sale | Ordinary Shares | 568 footnote F1 | $17.90 footnote F2 | $10K | |
| ||||||
| Barbara Harlin Bispham - Officer | Open-market sale | Ordinary Shares | 620 footnote F1 | $17.90 footnote F2 | $11K | |
| ||||||
| Joshua T. Brumm - Officer | Open-market sale | Ordinary Shares | 1,610 footnote F1 | $17.90 footnote F2 | $29K | |
| Joshua T. Brumm - Officer | Open-market sale | Ordinary Shares | 7,837 footnote F1 | $16.71 footnote F2 | $131K | |
| ||||||
 Jonathan McNeill - Officer | Open-market sale | Ordinary Shares | 731 footnote F1 | $17.90 footnote F2 | $13K | |
| Jonathan McNeill - Officer | Open-market sale | Ordinary Shares | 3,839 footnote F1 | $16.71 footnote F2 | $64K | |
| ||||||
| Fairmount Funds Management LLC - Director | Open-market purchase | Ordinary Shares | 853,450 | $14.50 | $12.38M | |
| Fairmount Funds Management LLC - Director | Open-market purchase | Pre-Funded Warrant (Right to Buy) | 525,897 | $14.50 | $7.62M | |
| Ryan Lynch - Officer | Open-market sale | Ordinary Shares | 465 footnote F1 | $17.99 footnote F2 | $8K | |
| ||||||
| Jan Pinkas - Officer | Open-market sale | Ordinary Shares | 1,288 footnote F1 | $17.99 footnote F2 | $23K | |
| ||||||
| Richard William Scalzo - Officer | Open-market sale | Ordinary Shares | 1,112 footnote F1 | $17.99 footnote F2 | $20K | |
| ||||||
| Barbara Harlin Bispham - Officer | Open-market sale | Ordinary Shares | 1,218 footnote F1 | $17.99 footnote F2 | $22K | |
| ||||||
| Ellie Eunkyung Im - Officer | Open-market sale | Ordinary Shares | 1,219 footnote F1 | $17.99 footnote F2 | $22K | |
| ||||||
| Jonathan McNeill - Officer | Open-market sale | Ordinary Shares | 20,549 footnote F1 | $17.99 footnote F2 | $370K | |
| ||||||
| Joshua T. Brumm - Officer | Open-market sale | Ordinary Shares | 42,305 footnote F1 | $17.99 footnote F2 | $761K | |
| ||||||
| Jonathan Violin - Director | Grant or award | Stock Option (Right to Buy) | 11,050 | $0.00 | - | |
| David Charles Lubner - Director | Grant or award | Stock Option (Right to Buy) | 11,050 | $0.00 | - | |
 Alexandra Balcom - Director | Grant or award | Stock Option (Right to Buy) | 11,050 | $0.00 | - | |
| Susan Moran - Director | Grant or award | Stock Option (Right to Buy) | 11,050 | $0.00 | - | |
| Fairmount Funds Management LLC - Director | Grant or award | Stock Option (Right to Buy) | 11,050 | $0.00 | - | |
| Jan Pinkas - Officer | Grant or award | Stock Option (Right to Buy) | 142,474 | $0.00 | - | |
| Fairmount Funds Management LLC - Director | Grant or award | Stock Option (Right to Buy) | 9,023 | $0.00 | - | |
| Susan Moran - Director | Grant or award | Stock Option (Right to Buy) | 9,023 | $0.00 | - | |
| Jonathan Violin - Director | Grant or award | Stock Option (Right to Buy) | 9,023 | $0.00 | - | |
| Alexandra Balcom - Director | Grant or award | Stock Option (Right to Buy) | 9,023 | $0.00 | - | |
| David Charles Lubner - Director | Grant or award | Stock Option (Right to Buy) | 9,023 | $0.00 | - | |
| BVF PARTNERS L P - 10% Owner | Other | Common Stock | 657,308 | - | - | |
| BVF PARTNERS L P - 10% Owner | Other | Common Stock | 556,617 | - | - | |
| BVF PARTNERS L P - 10% Owner | Other | Common Stock | 56,079 | - | - | |
| BVF PARTNERS L P - 10% Owner | Other | Pre-Funded Warrants to Purchase Common Stock | 304,098 | - | - | |
| BVF PARTNERS L P - 10% Owner | Other | Pre-Funded Warrants to Purchase Common Stock | 257,515 | - | - | |
| BVF PARTNERS L P - 10% Owner | Other | Pre-Funded Warrants to Purchase Common Stock | 25,944 | - | - | |
Item 2.02, 9.01
Item 8.01, 9.01
Item 2.02
Item 5.07
Recent CBIO Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Joshua T Brumm | Officer, Director | 9,013 | $155K | View on EDGAR | |
| Jonathan McNeill | Officer | 4,415 |
CBIO insider trading FAQ
What is the latest insider trade for CBIO?
CRESCENT BIOPHARMA, INC. (CBIO) had 8 insider filings in the last 90 days, with the most recent on 2026-09-18. The full record for CBIO runs to 27 Form 4 filings, the earliest from 2025-06-13. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying CBIO stock?
2 insider purchases of CBIO were filed in the last 90 days, totaling $20.00M.
How many insiders are selling CBIO stock?
9 insider sales of CBIO were filed in the last 90 days, totaling $286K.
Where can I see CBIO SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects CBIO Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Ryan Lynch view on EDGAR
- - Jan Pinkas view on EDGAR
- - Ellie Eunkyung Im view on EDGAR
- - Richard William Scalzo view on EDGAR
- - Barbara Harlin Bispham view on EDGAR
- - Joshua T. Brumm view on EDGAR
- - Jonathan McNeill view on EDGAR
- - Fairmount Funds Management LLC view on EDGAR
- - Ryan Lynch view on EDGAR
Related companies with recent insider activity
Learn more
- How to read insider buying signals
- What an open-market purchase by an insider can and cannot tell you.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where CBIO's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow CBIO with a 7-day demo
- CBIO on your watchlist
- Every CBIO Form 4 filing on record
- Up to 3 months of CBIO price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
